Table 4 Distribution of PfCRT polymorphism according to the drug sensitivities
From: In vitroantimalarial susceptibility and molecular markers of drug resistance in Franceville, Gabon
Drug | Profils | N | N° (%), of strains with polymorphism : (Pfcrt) | |||
|---|---|---|---|---|---|---|
HAPLOTYPE 72-76 | ||||||
CVIEK | CVIET | MIX | p | |||
CQ | Resistant (IC50 ≥ 100 nM) | 20 | 0 (0.0%) | 20 (100.0%) | 0 (0.0%) | 0.56 |
Sensitive (IC50 < 100 nM) | 26 | 1 (3.8%) | 25 (96.2%) | 0 (0.0%) | ||
MDAQ | Resistant (IC50 ≥ 60 nM) | 24 | 1 (4.2%) | 23 (95.8%) | 0 (0.0%) | 0.29 |
Sensitive (IC50 < 60 nM) | 22 | 0 (0.0%) | 22 (100%) | 0 (0.0%) | ||
MF | Resistant (IC50 ≥ 20 nM) | 11 | 0 (0.0%) | 11 (100.0%) | 0 (0.0%) | 0.58 |
Sensitive (IC50 < 20 nM) | 35 | 1 (2.9%) | 34 (97.1%) | 0 (0.0%) | ||
DHA | Reduced susceptibility (IC50 ≥ 10 nM) | 11 | 1 (9.1%) | 10 (90.9%) | 0 (0.0%) | 0.23 |
| Â | Sensitive (IC50 < 10 nM) | 35 | 0 (0.0%) | 35 (100.0%) | 0 (0.0%) | |